A Multitumor CME/MOC-Accredited Live Webinar Series

HER2-Positive and Triple-Negative Breast Cancer

Tuesday, January 30, 2024 5:00 PM – 6:00 PM ET

Faculty Ian E Krop, MD, PhD Priyanka Sharma, MD



Faculty



Ian E Krop, MD, PhD

Associate Cancer Center Director for Clinical Research Director, Clinical Trials Office Yale Cancer Center New Haven, Connecticut



MODERATOR Neil Love, MD Research To Practice Miami, Florida



Priyanka Sharma, MD

Frank B Tyler Professor in Cancer Research Division of Medical Oncology, Department of Internal Medicine Co-Program Leader Drug Discovery, Delivery and Experimental Therapeutics Program The University of Kansas Cancer Center Westwood, Kansas



Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc.



Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.



Dr Krop — Disclosures

Advisory Committees	AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Novartis, Seagen Inc
Consulting Agreements	AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group
Contracted Research	MacroGenics Inc, Pfizer Inc
Data and Safety MonitoringBoards/Committees	Merck, Novartis, Seagen Inc




Dr Sharma — Disclosures

Consulting Agreements	AstraZeneca Pharmaceuticals LP, Genzyme Corporation, Gilead Sciences Inc, GSK, Merck, Novartis, Pfizer Inc, Sanofi
Contracted Research	Gilead Sciences Inc, Merck, Novartis
Stock Options/Stock — Public Company	Amgen Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Sanofi




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Clinicians in the Audience, Please Complete the Pre- and Postmeeting Surveys





ONCOLOGY TODAY

WITH DR NEIL LOVE

Implications of Recent Data Sets for the Current and Future Management of Breast Cancer



ADITYA BARDIA, MD, MPH MASSACHUSETTS GENERAL HOSPITAL



SARA M TOLANEY, MD, MPH DANA-FARBER CANCER INSTITUTE



Dr Aditya Bardia and Dr Sara M Tolane Oncology Today with Dr Neil Love —

(30)

(15)







Meet The Professor Optimizing the Management of Myelofibrosis

Thursday, February 1, 2024 5:00 PM – 6:00 PM ET

Faculty Stephen T Oh, MD, PhD



A Multitumor CME/MOC-Accredited Live Webinar Series

Chronic Lymphocytic Leukemia

Tuesday, February 6, 2024 5:00 PM – 6:00 PM ET

> Faculty Lindsey Roeker, MD Jeff Sharman, MD



A Multitumor CME/MOC-Accredited Live Webinar Series

Gastroesophageal Cancers

Thursday, February 8, 2024 5:00 PM – 6:00 PM ET

Faculty Yelena Y Janjigian, MD Zev Wainberg, MD, MSc



A Multitumor CME/MOC-Accredited Live Webinar Series

Lymphoma

Tuesday, February 13, 2024 5:00 PM – 6:00 PM ET

Faculty Andrew M Evens, DO, MBA, MSc Sonali M Smith, MD



Year in Review: Clinical Investigator **Perspectives on the Most Relevant New Data Sets** and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series **Urothelial Bladder Cancer** Thursday, February 22, 2024 5:00 PM - 6:00 PM ET Faculty Shilpa Gupta, MD Thomas Powles, MBBS, MRCP, MD **Moderator** Neil Love, MD

JOIN US IN MARCH FOR THE RETURN OF

The Annual National General Medical Oncology Summit

A Multitumor CME/MOC- and NCPD-Accredited Educational Conference Developed in Partnership with Florida Cancer Specialists & Research Institute

MARCH 22-24, 2024

JW Marriott Miami Turnberry

To Learn More or to Register, Visit www.ResearchToPractice.com/Meetings/GMO2024

Agenda

INTRODUCTION: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024

MODULE 1: HER2-Positive Breast Cancer — Dr Krop

MODULE 2: Triple-Negative Breast Cancer — Dr Sharma



Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.



A Multitumor CME/MOC-Accredited Live Webinar Series

HER2-Positive and Triple-Negative Breast Cancer

Tuesday, January 30, 2024 5:00 PM – 6:00 PM ET

Faculty Ian E Krop, MD, PhD Priyanka Sharma, MD



Faculty



Ian E Krop, MD, PhD

Associate Cancer Center Director for Clinical Research Director, Clinical Trials Office Yale Cancer Center New Haven, Connecticut



MODERATOR Neil Love, MD Research To Practice Miami, Florida




Priyanka Sharma, MD

Frank B Tyler Professor in Cancer Research Division of Medical Oncology, Department of Internal Medicine Co-Program Leader Drug Discovery, Delivery and Experimental Therapeutics Program The University of Kansas Cancer Center Westwood, Kansas




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Clinicians in the Audience, Please Complete the Pre- and Postmeeting Surveys





ONCOLOGY TODAY

WITH DR NEIL LOVE

Implications of Recent Data Sets for the Current and Future Management of Breast Cancer



ADITYA BARDIA, MD, MPH MASSACHUSETTS GENERAL HOSPITAL



SARA M TOLANEY, MD, MPH DANA-FARBER CANCER INSTITUTE



Dr Aditya Bardia and Dr Sara M Tolane Oncology Today with Dr Neil Love —

(30)

(15)







Meet The Professor Optimizing the Management of Myelofibrosis

Thursday, February 1, 2024 5:00 PM – 6:00 PM ET

Faculty Stephen T Oh, MD, PhD



A Multitumor CME/MOC-Accredited Live Webinar Series

Chronic Lymphocytic Leukemia

Tuesday, February 6, 2024 5:00 PM – 6:00 PM ET

> Faculty Lindsey Roeker, MD Jeff Sharman, MD



A Multitumor CME/MOC-Accredited Live Webinar Series

Gastroesophageal Cancers

Thursday, February 8, 2024 5:00 PM – 6:00 PM ET

Faculty Yelena Y Janjigian, MD Zev Wainberg, MD, MSc



A Multitumor CME/MOC-Accredited Live Webinar Series

Lymphoma

Tuesday, February 13, 2024 5:00 PM – 6:00 PM ET

Faculty Andrew M Evens, DO, MBA, MSc Sonali M Smith, MD



Year in Review: Clinical Investigator **Perspectives on the Most Relevant New Data Sets** and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series **Urothelial Bladder Cancer** Thursday, February 22, 2024 5:00 PM - 6:00 PM ET Faculty Shilpa Gupta, MD Thomas Powles, MBBS, MRCP, MD **Moderator** Neil Love, MD

JOIN US IN MARCH FOR THE RETURN OF

The Annual National General Medical Oncology Summit

A Multitumor CME/MOC- and NCPD-Accredited Educational Conference Developed in Partnership with Florida Cancer Specialists & Research Institute

MARCH 22-24, 2024

JW Marriott Miami Turnberry

To Learn More or to Register, Visit www.ResearchToPractice.com/Meetings/GMO2024

Friday, March 22, 2024

6:30 PM - 7:00 PM **Welcome Reception** 7:00 PM - 9:00 PM **Keynote Session: ER-Positive Metastatic Breast Cancer** Erika Hamilton, MD Kevin Kalinsky, MD, MS Joyce O'Shaughnessy, MD Hope S Rugo, MD

Special Feature: Clinicians with Breast Cancer

Saturday, March 23, 2024

7:30 AM – 9:10 AM

Hodgkin and Non-Hodgkin Lymphoma

Ann S LaCasce, MD, MMSc Matthew Lunning, DO Kami Maddocks, MD Andrew D Zelenetz, MD, PhD

9:30 AM - 10:20 AM

Gynecologic Cancers

Bradley J Monk, MD David M O'Malley, MD

10:20 AM - 11:10 AM

Localized Breast Cancer; SABCS 2023 Review

Virginia Kaklamani, MD, DSc Kevin Kalinsky, MD, MS Joyce O'Shaughnessy, MD

11:10 AM - 12:00 PM

Metastatic Breast Cancer, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer; SABCS 2023 Review Erika Hamilton, MD

Virginia Kaklamani, MD, DSc Hope S Rugo, MD

Saturday, March 23, 2024

12:30 PM – 1:20 PM

Prostate Cancer

Emmanuel S Antonarakis, MD Rana R McKay, MD

1:20 PM – 2:10 PM

Urothelial Bladder Cancer

Matthew D Galsky, MD Jonathan E Rosenberg, MD

2:10 PM - 3:00 PM

Renal Cell Carcinoma

Eric Jonasch, MD Brian Rini, MD

3:20 PM - 4:10 PM

Targeted Therapy for Non-Small Cell Lung Cancer

Ibiayi Dagogo-Jack, MD Helena Yu, MD

4:10 PM - 5:00 PM

Nontargeted Treatments for Lung Cancer Edward B Garon, MD, MS Corey J Langer, MD

Sunday, March 24, 2024

7:30 AM – 8:20 AM

Multiple Myeloma

Natalie S Callander, MD Paul G Richardson, MD

8:20 AM - 9:10 AM

Gastroesophageal Cancers

Yelena Y Janjigian, MD Samuel J Klempner, MD

9:30 AM - 10:20 AM

Hepatobiliary Cancers

Ghassan Abou-Alfa, MD, MBA Richard S Finn, MD

10:20 AM - 11:10 AM

Colorectal Cancer

Kristen K Ciombor, MD, MSCI John Strickler, MD

11:10 AM – 12:00 PM Topic and faculty to be announced

A Multitumor CME/MOC-Accredited Live Webinar Series

HER2-Positive and Triple-Negative Breast Cancer

Tuesday, January 30, 2024 5:00 PM – 6:00 PM ET

Faculty Ian E Krop, MD, PhD Priyanka Sharma, MD



Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.



Dr Krop — Disclosures

Advisory Committees	AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Novartis, Seagen Inc
Consulting Agreements	AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group
Contracted Research	MacroGenics Inc, Pfizer Inc
Data and Safety MonitoringBoards/Committees	Merck, Novartis, Seagen Inc



Dr Sharma — Disclosures

Consulting Agreements	AstraZeneca Pharmaceuticals LP, Genzyme Corporation, Gilead Sciences Inc, GSK, Merck, Novartis, Pfizer Inc, Sanofi
Contracted Research	Gilead Sciences Inc, Merck, Novartis
Stock Options/Stock — Public Company	Amgen Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Sanofi



2023 Year in Review: HER2-Positive Breast Cancer

> Ian Krop MD PhD Yale Cancer Center January 2024

Yale University School of Medicine

Triple Negative Breast Cancer

Professor of Medicine University of Kansas Medical Center



Yalesense

THE UNIVERSITY OF KANSAS CANCER CENTER



Ian E Krop, MD, PhD

- Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 2023;24(3):273-85.
- Cortes J et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). ASCO 2023;Abstract LBA506.
- Holmes FA et al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. Eur J Cancer 2023;184:48-59.
- Chan A et al. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity
 of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast
 2023:67:94-101.



Ian E Krop, MD, PhD (continued)

- Jhaveri K et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: Outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023;34(10):885-98.
- André F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401(10390):1773-85.
- Hurvitz SA et al. **Trastuzumab deruxtecan versus trastuzumab emtansine** in patients with HER2positive metastatic breast cancer: Updated results from **DESTINY-Breast03**, a randomised, openlabel, phase 3 trial. *Lancet* 2023;401(10371):105-17.
- Krop IE et al. An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03. ASCO 2023;Abstract 1006.



Ian E Krop, MD, PhD (continued)

- Hurvitz SA et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. ESMO 2023;Abstract 3770.
- Pérez-García JM et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol 2023;25(1):157-66.
- Lin NU et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol 2023;9(2):197-205.
- Hurvitz S et al. HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. SABCS 2023;Abstract GS01-10.



Priyanka Sharma, MD

- Schmid P et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. ESMO 2023;Abstract LBA18.
- Gianni L et al. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. ESMO 2023;Abstract LBA19.
- Ignatiadis M et al. Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: Interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. SABCS 2023;Abstract GS01-03.
- Rugo HS et al. KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumaband in patients with immune-mediated AEs. ESMO Breast 2023;Abstract 191M0.
- Jiang Z et al. TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel (nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). ASCO 2023;Abstract LBA1013.



Priyanka Sharma, MD (continued)

- Loibl S et al. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. *Eur J Cancer* 2023;178:23-33.
- Bar Y et al. **Dynamic HER2-low status** among patients with triple negative breast cancer (TNBC): The impact of **repeat biopsies.** ASCO 2023;Abstract 1005.
- Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. ESMO 2023;Abstract 3760.
- Robson ME et al. **OlympiAD** extended follow-up for overall survival and safety: **Olaparib** versus chemotherapy treatment of physician's choice in **patients with a germline BRCA mutation** and HER2-negative metastatic breast cancer. *Eur J Cancer* 2023;184:39-47.



Priyanka Sharma, MD (continued)

- Khan QJ et al. Randomized trial of **fixed dose capecitabine** compared to standard dose capecitabine in metastatic breast cancer: The **X-7/7 trial**. ASCO 2023;Abstract 1007.
- Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase lb/ll study. ESMO 2023;Abstract 379MO.
- Krop IE et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol 2023;41(36):5550-60.
- Zhang J et al. First-in-human/phase I trial of **HS-20089, a B7-H4 ADC,** in patients with advanced solid tumors. ESMO 2023;Abstract 381O.



Agenda

INTRODUCTION: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024

MODULE 1: HER2-Positive Breast Cancer — Dr Krop

MODULE 2: Triple-Negative Breast Cancer — Dr Sharma



Agenda

INTRODUCTION: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – **ASCO Genitourinary Cancers Symposium 2024**

MODULE 1: HER2-Positive Breast Cancer — Dr Krop

MODULE 2: Triple-Negative Breast Cancer — Dr Sharma



Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Urothelial Bladder Cancer

Part 2 of a 2-Part CME Symposium Series Held in Conjunction with the 2024 ASCO Genitourinary Cancers Symposium

Friday, January 26, 2024 7:00 PM – 9:00 PM PT (10:00 PM – 12:00 AM ET)

Faculty

Matthew Milowsky, MD, FASCO Peter H O'Donnell, MD

Jonathan E Rosenberg, MD Arlene Siefker-Radtke, MD

Moderator Evan Y Yu, MD



Consulting Faculty Questions

Perspectives from the breast cancer experience: Identification and management of T-DXd-associated side effects



Neil Love, MD



Priyanka Sharma, MD



Agenda

INTRODUCTION: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024

MODULE 1: HER2-Positive Breast Cancer — Dr Krop

MODULE 2: Triple-Negative Breast Cancer — Dr Sharma



De-escalation of Perioperative Treatment

HER2-Positive Breast Cancer

- Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 2023;24(3):273-85.
- Cortes J et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). ASCO 2023;Abstract LBA506.



Third Annual National General Medical Oncology Summit

Friday, March 22, 2024 — 7:00 PM – 9:00 PM

Keynote Session Special Feature: Clinicians with Cancer

What adjuvant treatment do you think a medical oncologist would prefer to receive for a subcentimeter, node-negative, HER2-positive breast cancer?

The era of personalized medicine in HER2+ EBC


- The favorable outcomes of HER2+ breast cancers provide opportunity to:
 - De-escalate therapy for lower risk patients to reduce the toxicities of treatment
 - Escalate therapy for minority of patients who are risk for recurrence despite maximal current management

APT: Conclusions

- Paclitaxel and trastuzumab (TH) is associated with excellent outcomes and is a standard of care for patients with stage I HER2+ breast cancer
 - Favorable outcomes for both ER+ and ER- HER2+ cancers and for T1C cancers
 - Not all patients require adjuvant trastuzumab-based chemotherapy (particularly T1aN0)

• Is there a role for T-DM1 in stage I pts?

PHERGain: Can PET response be used to guide therapy de-escalation in HER2+ EBC?



C: Carboplatin; D: Docetaxel; EBC: Early breast cancer; ETx: Endocrine therapy (letrozole post-menopausal/tamoxifen pre-menopausal), Adjuvant ETx up to 3 years from surgery; PET: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography; H: Trastuzumab SC; HER2: Human Epidermal Growth Factor Receptor 2; iDFS: Invasive disease-free survival; MRI: Magnetic resonance Imaging; P: Pertuzumab IV; R: Randomization; TCHP: Trastuzumab, pertuzumab, docetaxel, and carboplatin. ⁺ All hormonal receptor-positive patients received ETx concomitantly with PH (except on chemotherapy).

- PET RESPONDERS: RECIST responders after cycle 2 with SUV_{max} reduction ≥40%.
- pCR, Pathological complete response (ypT0/isN0)

#ASCO23

2023 ASCO

ANNUAL MEETING


PRESENTED BY: Dr. JAVIER CORTÉS MD PhD

Courtesy of Ian E Krop, MD, PhD

phergain



PHERGain Primary Endpoint: pCR in ¹⁸F-FDG-PET responders in group B



pCR was observed in patients with both HER2++ and HER2+++, pts with stage II and stage III, and pts ER+ and ER-.

Pérez-García, JM, et al. (2021). Lancet Oncol, 22(6), 858-871.

CI: Confidence interval; PET: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography; pCR: Pathological complete response (ypT0/isN0).



#ASCO23 PRESENTED BY: Dr. JAVIER CORTÉS MD PhD

Courtesy of Ian E Krop, MD, PhD

phergain



PHERGain Conclusions

- PET-guided de-escalation approach yields generally favorable overall outcome: 3-year iDFS of 95.4%
 - Allows 30% of pts to omit chemotherapy
 - Note relatively short-term follow-up
- How does this compare to short course of neoadj chemo (eg THP) with pCR rate of ≈55% and presumably no need for additional chemotherapy (eg COMPASS pCR trial)?
- Can we use upfront biomarker selection to enrich these types of approaches with patients most likely to do well with de-escalation approach?

Neratinib in the Post-Adjuvant and Metastatic Settings

HER2-Positive Breast Cancer

- Holmes FA et al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. *Eur J Cancer* 2023;184:48-59.
- Chan A et al. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity
 of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast
 2023:67:94-101.
- Jhaveri K et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: Outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023;34(10):885-98.



Third Annual National General Medical Oncology Summit

Friday, March 22, 2024 — 7:00 PM – 9:00 PM

Keynote Session Special Feature: Clinicians with Cancer

How do you think a medical oncologist who had recently completed adjuvant therapy for HER2-positive breast cancer would think through the decision to receive postadjuvant neratinib?

ExteNET: Cumulative incidence of CNS disease as 1st site of recurrence

	CNS Events (No. Patients)	Cumulative Incidence of CNS Recurrences at 5 Years, % (95% CI)		
Population or Subgroup	Neratinib	Placebo	Neratinib	Placebo	
HR ⁺ /≤ 1-year population	4 (670)	12 (664)	0.7 (0.2-1.7)	2.1 (1.1-3.5)	
Nodal status					
Positive	4 (540)	10 (539)	0.8 (0.3-2.0)	2.2 (1.1-3.8)	
Negative	0 (130)	2 (125)	0 (NE)	1.9 (0.4-6.0)	
Prior trastuzumab regimen					
Concurrent	2 (411)	8 (415)	0.6 (0.1-1.9)	2.3 (1.1-4.3)	
Sequential	2 (259)	4 (249)	0.9 (0.2-3.0)	1.8 (0.6-4.3)	
Adjuvant or neoadjuvant therapy					
Adjuvant	3 (508)	6 (472)	0.7 (0.2-2.0)	1.5 (0.6-3.0)	
Neoadjuvant	1 (162)	6 (192)	0.7 (0.1-3.3)	3.7 (1.5-7.4)	
pCR status ^a					
No	1 (131)	5 (164)	0.8 (0.1-4.0)	3.6 (1.3-7.8)	
Yes	0 (17)	1 (21)	O (NE)	5.0 (0.3-21.2)	

Who Should Receive Neratinib?

- Neratinib benefit (relative and absolute) in ER+HER2+ high risk patients
 - Must be balanced against toxicity risk
- No data giving neratinib after pertuzumab or T-DM1
 - All patients at sufficiently high risk to receive neratinib will have received pertuzumab and T-DM1
- So who should receive it?
 - Unclear, but my opinion is that it is reasonable option to consider in ER+ patients with positive nodes after neoadjuvant therapy

How to mitigate neratinib induced diarrhea?

• Neratinib dose escalation, along with loperamide, is associated with relatively low rates of gr3 diarrhea

- Most pts who get through 1st cycle have low rate of drug discontinuation due to diarrhea
 - Patient education is key

SUMMIT: Does neratinib have activity in breast cancers with somatic HER2 mutations?

- Somatic HER2 mutations seen in 3-5% of HR+ HER2 non-amplified cancers
 - More common in lobular cancers (5-8%)
 - May be acquired with endocrine resistance
- SUMMIT trial is basket study evaluating neratinib alone and in combination in patients with HER2 mutant breast cancer
 - Initial results showed single agent activity: 17% ORR in HR+ HER2mutant MBC
 - Combination of neratinib and fulvestrant: 30% ORR
 - ctDNA data suggested secondary HER2 mutations or HER2 amplification as mechanism of resistance
- Data led to cohort of neratinib + fulvestrant + trastuzumab (NFT) performed (n=71) in pts previously treated with CDK4/6 inhibitor
 - Randomized subset: F vs FT vs NFT (n=21)

Courtesy of Ian E Krop, MD, PhD

Jhaveri et al, Annals of Oncology 34:885 2023

SUMMIT: Does neratinib have activity in breast cancers with somatic HER2 mutations?

Parameter	Non-randomized + randomized HR+, prior CDK4/6i (N+F+T, <i>N</i> =57)	Random prior	nized HR+, CDK4/6i Г, <i>n=</i> 7)	After crossover from F+T to N+F+T (<i>n=</i> 4)	Randomized HR+, prior CDK4/6i (F, <i>n</i> =7)	After crossover from F to N+F+T (<i>n=</i> 6)
Objective response (confirmed	22 (39)		0	1 (25)	0	2 (33)
CR or PR) ^b , n (%)						
CR	1 (2)		0	0	0	0
PR	21 (39)		0	1 (25)	0	2 (33)
Best overall response (confirmed or unconfirmed PR or CR), n (%)	29 (51)		0	1 (25)	0	3 (50)
Median DOR ^⁰ , months (95% CI)	14.4 (6.4–21.7)	No re	sponse	6.2 (NE–NE)	No response	6.3 (6.2–6.4)
Clinical benefit ^d , n (%)	31 (54)		0	1 (25)	0	5 (83)
Median PFS [°] , months (95% CI)	8.3 (6.0–15.1)	3.9 ('	.9–4.1)	5.8 (3.3–8.3)	4.1 (1.6–4.1)	9.5 (3.9–NE)

- ORR: 63% V777L
 24% L755S
 80% dual mutation
- HER2 expression level or FISH amplification were not assoc with ORR
- Grade 3 diarrhea was 53% with triplet despite loperamide prophylaxis

SUMMIT: Conclusion

- Neratinib + fulvestrant has clinically meaningful activity in patients with ER+HER2mutant MBC
 - Addition of trastuzumab may further increase benefit
 - Substantial Gr3 diarrhea consider neratinib dose escalation
- Neratinib based therapy can be considered an effective treatment option for ER+HER2mutant MBC
 - Included in NCCN guidelines
- These data provide additional support for obtaining somatic tumor sequencing (tissue or ctDNA) in the MBC setting

Sequencing of Therapy for HER2-Positive mBC

HER2-Positive Breast Cancer

- Hurvitz SA et al. **Trastuzumab deruxtecan versus trastuzumab emtansine** in patients with HER2positive metastatic breast cancer: Updated results from **DESTINY-Breast03**, a randomised, openlabel, phase 3 trial. *Lancet* 2023;401(10371):105-17.
- André F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401(10390):1773-85.
- Krop IE et al. An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03. ASCO 2023;Abstract 1006.



DESTINY-Breast03: Adjudicated Drug-Related Interstitial Lung Disease/Pneumonitis

	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any grade
T-DXd (n = 257)	11 (4.3)	26 (10.1)	2 (0.8)	0	0	39 (15.2)
T-DM1 (n = 261)	4 (1.5)	3 (1.1)	1 (0.4)	0	0	8 (3.1)

- Adjudicated drug-related ILD/pneumonitis rates were similar to other mBC trials with T-DXd^{1,2}
- With longer treatment exposure and follow-up, the ILD/pneumonitis rate increased from 10.5% in the PFS interim analysis³ to 15.2%
 - There were 4 additional grade 1, 8 additional grade 2, and no additional grade 3 events
- The overall incidence of grade 3 events (0.8%) was the same as in the PFS interim analysis³
- There were no adjudicated drug-related grade 4 or 5 events

ILD, interstitial lung disease; mBC, metastatic breast cancer; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan. 1. Modi S et al. N Engl J Med 2020; 382(7): 610-21. 2. Powell CA et al. ESMO Open 2022; 7(4): 100554. 3. Cortes J et al. N Engl J Med. 2022;386:1143-1154.

Hurvitz SA et al. Lancet 2023;401:105

DB-03 Conclusions

- Establishes T-DXd role as preferred 2nd line SOC for most patients
 - Unprecedented levels of activity and reassuring ILD data
- Should there be a different SOC for pts with active CNS metastases?



Adverse Events of Special Interest: ILD and LV Dysfunction

Adjudicated as Drug-related ILD ^a							
n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any Grade	
T-DXd (n = 404)	11 (2.7)	26 (6.4)	3 (0.7)	0	2 (0.5)	42 (10.4)	
TPC (n = 195)	0	0	1 (0.5)	0	0	1 (0.5)	

 Median time to onset of adjudicated drug-related ILD was 209.5 days (range, 41-638 days) with T-DXd

LV dysfunction^b

- In the T-DXd arm, 18 (4.5%) patients experienced an LV dysfunction event^c
 - 2 (0.5%) patients had a grade \geq 3 event
- In the TPC arm, 3 (1.5%) patients experienced an LV dysfunction^d
 - 1 (0.5%) patient had a grade \geq 3 event

ILD, interstitial lung disease; LV, left ventricular; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.

^aThe safety analysis set includes all randomly assigned patients who received at least 1 dose of study treatment. ^bLeft ventricular dysfunction included preferred terms of acute left ventricular failure, acute right ventricular failure, cardiac failure acute, cardiac failure, cardiac failure cardiac failure, ejection fraction decreased, left ventricular failure, right ventricular failure, ventricular failure, and left ventricular dysfunction. ^c17 ejection fraction decreased (2 grade >3), 1 LV dysfunction (grade 1). ^d ejection fraction decreased (grade 1), 2 cardiac failure (1 grade >3).

DB-02 Conclusions

- Provides first randomized data demonstrating benefit of one ADC after cancer has progressed on a different ADC
 - Provides support for paradigm of treating pts with HER2+ breast cancer with sequential ADCs with different payloads


Does age impact efficacy or tolerability of T-DXd?

- Older patients experience higher rates of toxicity from chemotherapy
- To determine if this effect is observed with T-DXd, an analysis of pts <65yo vs ≥65 was conducted in pooled data from DB-01, -02, 03



Descriptive Efficacy According to Age for T-DXd^a

Median Progression Free Survival



• Efficacy in patients aged <65 and ≥65 years treated with T-DXd was generally similar; however no formal comparison was made

PRESENTED BY: Ian Krop, MD, PhD


#ASCO23

ANNUAL MEETING

Median Overall Survival

	DESTINY-Breast01		DESTINY-Breast02		DESTINY-Breast03	
	<65	≥65	<65	≥65	<65	≥65
	(n = 140)	(n = 44)	(n = 321)	(n = 85)	(n = 212)	(n = 49)
mOS, months	28.1	30.9	NR	30.2	NR	NR
(95% Cl)	(23.3-36.1)	(21.9-NE)	(35.5-NE)	(22.3-39.2)	(40.5-NE)	(26.3-NE)

12-month Landmark Overall Survival




^aEfficacy data was not pooled due to bias induced by the heterogeneity of the study population. Trial data cutoffs; DESTINY-Breast01: March 26, 2021; DESTINY-Breast02: June 30, 2022; DESTINY-Breast03: July 25, 2022. mOS, median overall survival; NE, not estimable; NR, not reached; T-DXd, trastuzumab deruxtecan.



Courtesy of Ian E Krop, MD, PhD



Relative Dose Intensity



 Relative dose intensity was similar between <65 and ≥65 age groups, regardless of treatment received

^aRelative dose intensity (%) = (dose intensity/planned dose intensity) ×100. DB, DESTINY-Breast; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.





Courtesy of Ian E Krop, MD, PhD



Most Common Grade ≥3 Drug-related TEAEs in ≥5% of Patients

	T-DXd Pool		TPC (DB-02)		T-DM1 (DB-03)				
	<65 (n = 668)	≥65 (n = 177)	≥75 (n = 33)	<65 (n = 157)	≥65 (n = 38)	≥75 (n = 8)	<65 (n = 204)	≥65 (n = 57)	≥75 (n = 8)
Grade ≥3ª drug-related TEAEs, n (%)	291 (43.6)	96 (54.2)	13 (39.4)	48 (30.6)	12 (31.6)	5 (62.5)	82 (40.2)	28 (49.1)	3 (37.5)
Neutropenia ^b	117 (17.5)	41 (23.2)	4 (12.1)	5 (3.2)	1 (2.6)	1 (12.5)	6 (2.9)	3 (5.3)	0
Fatigue ^c	52 (7.8)	20 (11.3)	5 (15.2)	1 (0.6)	1 (2.6)	1 (12.5)	2 (1.0)	0	0
Nausea	43 (6.4)	15 (8.5)	4 (12.1)	3 (1.9)	0	0	0	1 (1.8)	0
Anemiad	42 (6.3)	20 (11.3)	3 (9.1)	1 (0.6)	0	0	6 (2.9)	6 (10.5)	1 (12.5)
Leukopenia ^e	42 (6.3)	15 (8.5)	2 (6.1)	0	0	0	3 (1.5)	0	0
Lymphopenia ^f	28 (4.2)	11 (6.2)	1 (3.0)	2 (1.3)	0	0	2 (1.0)	1 (1.8)	0
Thrombocytopenia ^g	28 (4.2)	9 (5.1)	0	2 (1.3)	0	0	47 (23.0)	19 (33.3)	2 (25.0)
Transaminases increased ^h	18 (2.7)	1 (0.6)	0	1 (0.6)	1 (2.6)	0	16 (7.8)	4 (7.0)	0
Diarrhea	9 (1.3)	4 (2.3)	0	10 (6.4)	2 (5.3)	1 (12.5)	2 (1.0)	0	0

• Patients ≥65 years of age experienced more grade ≥3 TEAEs across all trials

^aGrade ≥3 drug-related TEAEs present in ≥5% of patients, sorted in descending order of frequency in the T-DXd pooled arm for the <65 years age group. Grade ≥3 drug-related TEAEs calculated in all patients in the analysis set. ^bNeutropenia includes the preferred terms neutrophil count decreased and neutropenia. ^cFatigue includes the preferred terms fatigue, asthenia, malaise, and lethargy. ^dAnemia includes the preferred terms hemoglobin decreased, red blood cell count decreased, anemia, and hematocrit decreased. ^eLeukopenia includes the preferred terms white blood cell count decrease and leukopenia. ^fLymphopenia includes the preferred terms platelet count decreased and thrombocytopenia. ^hTransaminases increased includes the preferred terms transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic function abnormal, and liver function test increased. T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TEAE, treatment emergent adverse event; TPC, treatment of physician's choice.



#ASCO23





Adjudicated Drug-related ILD/Pneumonitis^a

		T-DXd Pool			TPC (DB-02)			T-DM1 (DB-03)		
	<65 (n = 668)	≥65 (n = 177)	≥75 (n = 33)	<65 (n = 157)	≥65 (n = 38)	≥75 (n = 8)	<65 (n = 204)	≥65 (n = 57)	≥75 (n = 8)	
Any grade, n (%)	79 (11.8)	31 (17.5)	5 (15.2)	0	1 (2.6)	0	6 (2.9)	2 (3.5)	1 (12.5)	
1	21 (3.1)	7 (4.0)	0	0	0	0	3 (1.5)	1 (1.8)	0	
2	48 (7.2)	20 (11.3)	5 (15.2)	0	0	0	2 (1.0)	1 (1.8)	1 (12.5)	
3	4 (0.6)	3 (1.7)	0	0	1 (2.6)	0	1 (0.5)	0	0	
4	0	0	0	0	0	0	0	0	0	
5	6 (0.9)	1 (0.6)	0	0	0	0	0	0	0	

- Rates of adjudicated ILD/pneumonitis were generally higher in patients ≥65 years of age across all trials compared to patients <65 years of age
- Most drug-related ILD/pneumonitis cases were of low grade

PRESENTED BY: Ian Krop, MD, PhD

#ASCO23

^aNo ILD/pneumonitis cases were pending adjudication at the respective data cutoff dates (DESTINY-Breast01: March 26, 2021; DESTINY-Breast02: June 30, 2022; DESTINY-Breast03: July 25, 2022). ILD, interstitial lung disease; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.





- Results of this pooled analysis indicate that T-DXd remains an effective treatment option for patients ≥65 years of age
 - mPFS and confirmed ORR by BICR were similar with T-DXd in patients <65 and ≥65 years of age within each trial
- The safety profile of T-DXd was acceptable across all age subgroups
 - Patients ≥65 years of age experienced more grade ≥3 TEAEs across all trials
- Further research/real-world evidence studies for older patients, also addressing aspects of comorbidities and frailty, would be informative

T-DXd may be considered as an effective option for patients across all age subgroups with an acceptable safety profile

BICR, blinded independent central review; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer; mPFS, median progression free survival; ORR, objective response rate; T-DXd, trastuzumab deruxtecan; TEAE, treatment emergent adverse event.







HER2-Positive Brain Metastases


HER2-Positive Breast Cancer

- Hurvitz S et al. HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. SABCS 2023;Abstract GS01-10.
- Hurvitz SA et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. ESMO 2023; Abstract 3770.
- Pérez-García JM et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. *Neuro Oncol* 2023;25(1):157-66.



Courtesy of Ian E Krop, MD, PhD

HER2CLIMB-02 Study Design



The primary analysis for PFS was planned after ≈331 PFS events to provide 90% power for hazard ratio of 0.7 at two-sided alpha level of 0.05. The first of two interim analyses for OS was planned at the time of the primary PFS analysis, if the PFS result was significantly positive^b.


No prior HER2 TKI or T-DXd

NCT03975647. https://www.clinicaltrials.gov/study/NCT03975647. Accessed Oct 5, 2023.

a Patients who received prior tucatinib, afatinib, T-DXd, or any investigational anti-HER2, anti-EGFR, or HER2 TKIs were not eligible. Patients who received lapatinib and neratinib were not eligible if the drugs were received within 12 months of starting study treatment, and patients who received pyrotinib for recurrent or metastatic breast cancer were not eligible. These patients were eligible if the drugs were given for <21 days and were discontinued for reasons other than disease progression or severe toxicity. b Subsequent OS analyses are planned upon 80% and 100% of required events for the final OS analysis.

1L, first-line; BID, twice daily; cORR, confirmed objective response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenously; LA/MBC, locally advanced or metastatic breast cancer; OS, overall survival; PFS, progression-free survival; PO, orally; R, randomization; RECIST, Response Evaluation Criteria in Solid Tumors; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TKIs, tyrosine kinase inhibitors. Date of data cutoff: Jun 29, 2023. Patients were enrolled from Oct 8, 2019, to Jun 16, 2022.

HER2CLIMB-02: PFS in Patients with Brain Metastases



a The outcome was not formally tested.

HR, hazard ratio; PFS, progression-free survival; T-DM1, trastuzumab emtansine.

Date of data cutoff: Jun 29, 2023.

HER2CLIMB-02: Conclusion

- Addition of tucatinib to T-DM1 modestly improves PFS
 - Relative benefit larger in patients with CNS disease
 - No OS benefit, but data immature
 - Increased toxicity appears manageable, but ≈20% drug discontinuation
 - Caveat: data are in T-DXd naïve patients

- Unclear whether tucatinib should be used with T-DM1 or trastuzumab/capecitabine
 - Is there a role for using it in both combinations sequentially?


Are there other options for active brain mets besides TKIs?

 Does trastuzumab deruxtecan have activity in HER2+ brain metastases?

 Dogma had been that large biologics like ADCs cannot cross the blood brain barrier



Retrospective Exploratory Pooled Analysis Plan¹⁻³



The BM and non-BM pools were determined by BICR at baseline among all patients based on mandatory brain CT/MRI screening

BICR, blinded independent central response; BM, brain metastasis; CNS, central nervous system; CR, complete response; CT, computed tomography; DB, DESTINY-Breast; DoR, duration of response; HER2, human epidermal growth factor receptor 2; IC, intracranial; mBC, metastatic breast cancer; MRI, magnetic resonance imaging; ORR, objective response rate; PFS, progression-free survival; PR, partial response; R, randomization; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice (trastuzumab/capecitabine or lapatinib/capecitabine).


Data for patients in the 5.4 mg/kg T-DXd arms were pooled from the DB-01, DB-02, and DB-03 trials. Comparator data were pooled from the DB-02 and DB-03 trials. All three studies were conducted in unresectable/mBC; HER2 status was confirmed centrally; and a documented radiographic progression after most recent treatment was required.

^aThe presence of BMs was not a stratification factor. ^bData Cutoff: March 26, 2021. ^cData Cutoff: June 30, 2022. ^dData Cutoff: May 21, 2021. ^e5.4 mg/kg Q3W. ^f3.6 mg/kg Q3W.

1. Modi S et al. *N Engl J Med.* 2020; 382:610-621 [article and supplementary appendix]. 2. André F et al. *The Lancet.* 2023. https://doi.org/10.1016/S0140-6736(23)00725-0 [article and supplementary appendix]. 3. Cortes J et al. *N Engl J Med.* 2022; 368(12):1143-1154 [article and supplementary appendix].



Small studies of T-DXd in patients with HER2+ progressive brain metastases



Bartsch R, et al. Nat Med. 28:1840. 2022 Kabraji S, et al. Clin Cancer Res. 29:174. 2023 Pérez-García et al. Neuro-Oncology 25:157. 2023

Courtesy of Ian E Krop, MD, PhD


T-DXd CNS Studies Conclusions

 Pooled analysis of DB-01,-02,-03 show strong evidence of activity of T-DXd in patients with both stable and active brain mets

Most pts had previously untreated and asymptomatic brain mets

- Several additional studies (all small) of T-DXd also demonstrate intracranial activity of T-DXd in patients with progressive brain mets
- Together, these studies provide compelling evidence of intracranial activity of T-DXd

Approach to Therapy for Metastatic HER2+ Disease



Agenda

INTRODUCTION: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024

MODULE 1: HER2-Positive Breast Cancer — Dr Krop

MODULE 2: Triple-Negative Breast Cancer — Dr Sharma



Neoadjuvant Chemoimmunotherapy

Triple-Negative Breast Cancer

- Schmid P et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. ESMO 2023;Abstract LBA18.
- Gianni L et al. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. ESMO 2023;Abstract LBA19.
- Ignatiadis M et al. Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: Interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. SABCS 2023;Abstract GS01-03.




Third Annual National General Medical Oncology Summit

Friday, March 22, 2024 — 7:00 PM – 9:00 PM

Keynote Session Special Feature: Clinicians with Cancer How do you think a medical oncologist with localized TNBC would think through the choice and duration of chemotherapy to receive in combination with neoadjuvant pembrolizumab? How would they approach adjuvant therapy?

KEYNOTE-522: IA6



KN-522: IA6 summary

- After a median follow-up of >5 years, neoadjuvant pembro + chemo followed by adjuvant pembrolizumab continues to show a clinically meaningful improvement in EFS compared with neoadjuvant chemo alone
- The EFS benefit was generally consistent in subgroups based on TNM stage (II/III) and nodal status (+/-)
- Follow-up for OS is ongoing
- EFS improvement in pembrolizumab group was observed regardless of pCR outcome
 - Priven primarily by neoadjuvant pembrolizumab. ? What is the relative contribution of adjuvant pembrolizumab

pCR/RD: locally assessed. ? Reliability of local assessment of pCR in an international trial

NeoTRIPaPDL1: Atezolizumab plus weekly Carboplatin + Nab-paclitaxel

 $\Delta + 14.96\%$


72%


(25)

86.96%

(23)

IC2/3






pCR, positive PD-L1, earlier stage as well as higher sTILs were all prognostic and linked to better EFS, but they were not predictive of atezolizumab benefit

Gianni et al Annal Oncol 2022, Gianni et al ESMO 2023

Why no pCR or EFS Benefit in NeoTRIPaPDL1?

- >PDL-1 vs PD-1 inhibitor
 - ➢ IMpassion031: pCR better, EFS numerically better with atezolizumab
 - >mTNBC: Atezo plus taxane not statistically superior to taxane (IMpassion130, 131)
- Chemotherapy backbone: no anthracycline
- >Anatomic risk of enrolled population:
 - >90% with node positive disease (compared to 30% in IMpassion031)
 - With high anatomical risk would efficacy be more in line with what is observed in mTNBC?
- Differences in tumour biology: Higher TILs in chemo alone arm giving the control arm inherent better prognosis compared to IO arm
- ≻Chance

ALEXANDRA/IMpassion030 phase 3 trial : Adjuvant IO (without neoadjuvant component)





Timing of IO matters: Neoadjuvant more effective than adjuvant IO Previous Animal data consistent with clinical findings (Liu et al Cancer Discover 2015) Similar observations in other cancer like Melanoma

Ignatiadis SABCS 2023

Courtesy of Priyanka Sharma, MD

NeoPACT: Carboplatin + Docetaxel+ Pembrolizumab





Provide data on an alternative anthracycline-free chemoimmunotherapy regimen for patients who are not eligible/wish to avoid anthracycline-based regimens and support further evaluation of this regimen as a chemotherapy de-escalation strategy in randomized studies (On going SWOG 2212 trial)

Immune enrichment assessed by sTILs, PD-L1 or IO response signature was noted in almost 50% of patients and was associated with high pCR rates exceeding 70%.

Courtesy of Priyanka Sharma, MD


Sharma et al JAMA Oncology 2023

irAE: KN-522 real world toxicity

Real World data N=577 (17 sites), 18.2% Blacks

Adverse drug events(ADE) causing dose reduction	37.6%
ADE leading to early discontinuation	39.5%
irAE, all grades	71%
irAE <u>></u> 3	33.5%

	Blacks	Whites	р	
pCR	52.3%	55.9%	0.6	
<u>></u> 3 irAE	20.9%	33.8%	0.01	
Hospitalization rate	39%	36%	0.5	



Hofherr et al SABCS 2023, Jacob et al SABCS 2023

Courtesy of Priyanka Sharma, MD

Chemoimmunotherapy for mTNBC

Triple-Negative Breast Cancer

- Rugo HS et al. KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumaband in patients with immune-mediated AEs. ESMO Breast 2023;Abstract 191M0.
- Jiang Z et al. TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel (nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). ASCO 2023;Abstract LBA1013.



KEYNOTE-355: Outcomes in Patients Who Discontinued Chemotherapy Before Pembrolizumab and in Patients With Immune Mediated AEs

 KEYNOTE-355 (NCT02819518): phase 3, randomized, double-blind study of pembrolizumab 200 mg Q3W plus chemotherapy^a vs placebo plus chemotherapy^a for previously untreated, locally recurrent inoperable or metastatic TNBC

	PD-L1 (PD-L1 CPS ≥10		PD-L1 CPS ≥1 ^b		ITT°	
	Pembro + Chemo	Placebo + Chemo	Pembro + Chemo	Placebo + Chemo	Pembro + Chemo	Placebo + Chemo	
Median OS, mo ¹	23.0	16.1	17.6	16.0	17.2	15.5	
HR (95% CI)		55–0.95) ^D = 0.0093 ^{d,2}	0.86 (0.	72–1.04)	0.89 (0.	76–1.05)	
Median PFS, mo ³	9.7	5.6	7.6	5.6	7.5	5.6	
HR (95% CI)		49–0.86) <i>P</i> = 0.0012	0.74 (0.	61–0.90)	0.82 (0.6	69–0.97)	

PFS and OS in Patients treated with pembro+ chemo with or without irAE


Analysis Population	N	Median Pembro Treatment Duration (range), mo	Median Chemo Treatment Duration (range), mo	Median (95% CI) PFS ^b , mo	Median (95% CI) OS ^ь , mo
All patients as treated					
Patients who had immune- mediated AEs	149	8.8 (0.0–29.0)	7.2 (0.3–41.7)	9.7 (8.0–11.6)	23.9 (20.6–28.6)
All	562	5.6 (0.0-32.2)	5.1 (0.0–48.8)	7.5 (6.3-7.7)	17.2 (15.3–19.0)
PD-L1 CPS ≥1					
Patients who had immune- mediated AEs	109	8.8 (0.7–29.0)	7.3 (1.0–34.8)	9.8 (8.0–16.5)	26.3 (21.2–32.7)
All	421	5.9 (0.0-32.2)	5.1 (0.0-48.8)	7.6 (6.6-8.0)	17.6 (15.5–19.5)
PD-L1 CPS 210 🗛		patients irAE			
Patients who had immune- mediated AEs	64	10.4 (0.8–29.0)	8.4 (2.3–34.8)	11.8 (9.5–NR)	35.6 (26.3–NR)
All	219	7.6 (0.0-32.2)	5.8 (0.0-45.8)	9.7 (7.6-11.3)	22.8 (18.8–26.2)

*Only treated patients in the part 2 pembrolizumab plus chemotherapy group were analyzed. ^bPer Kaplan-Meier method. Data cutoff date: June 15, 2021.

- Exploratory analyses to evaluate efficacy in patients who: –Had disease control and discontinued chemotherapy before pembrolizumab
- -Experienced immune-mediated AEs

Rugo et al ESMO 2023

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel (nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). ASCO 2023;Abstract LBA1013



N=531, Toripalimab:PD1 antibody

-PDL1 assay (CPS, JS311 antibody): CPS > 1 considered PDL1+ve, **56% PDL1+ve**

-Data presented: prespecified IA of PFS in PDL1+ population and ITT

-93% first line, 28-31% de-novo metastatic, Prior taxane in only 15% *Liu et al ASCO* 2023

Median PFS 8.4 vs 5.6 months, HR 0.65

Courtesy of Priyanka Sharma, MD

TORCHLIGHT: Summary

- At IA 1 PFS prolonged with addition of toripalimab to nab-paclitaxel in PDL1+ population
 - HR and Median PFS very similar to KN355
- PFS in ITT did not meet the prespecified hierarchal testing boundary at IA 1
- OS data is immature, Follow up ongoing
- PDL1 testing by yet another assay and threshold
- Enrollment only in China: ? approval path for other countries/regions
- Limited toxicity data provided


PARP Inhibitors


Triple-Negative Breast Cancer


 Robson ME et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Eur J Cancer* 2023;184:39-47.



OlympiAD: Extended follow-up for overall survival and safety







Median follow-up: 25.7 months longer than that previously reported for OS and safety

Median OS: Olaparib (19.3 months) vs TPC (17.1 months) HR 0.90 (0.66 1.23)

Courtesy of Priyanka Sharma, MD

Robson et al European Journal of Cancer 184 (2023) 39e47

PARPi for MBC

SYSTEMIC THERAPY REGIMENS FOR RECURRENT UNRESECTABLE (LOCAL OR REGIONAL) OR STAGE IV (M1) DISEASE^a SYSTEMIC THERAPY REGIMENS FOR RECURRENT UNRESECTABLE (LOCAL OR REGIONAL) OR STAGE IV (M1) DISEASE^a

HF	R-Positive and HER2-Negative with	Visceral Crisis [†] or Endocrine Refractory
Setting	Subtype/Biomarker	Regimen
First Line	No germline BRCA1/2 mutation ^b	Systemic chemotherapy see BINV-Q (5)
	Germline BRCA1/2 mutation ^b	PARPi (olaparib, talazoparib) ^c (Category 1, preferred)
Second Line	HER2 IHC 1+ or 2+/ISH negatived	Fam-trastuzumab deruxtecan-nxki ^e (Category 1, preferred)
	Not a candidate for fam-trastuzumab	Sacituzumab govitecan ^f (Category 1, preferred)
	deruxtecan- nxki	Systemic chemotherapy see BINV-Q (5)
Third Line and beyond	Any	Systemic chemotherapy see BINV-Q (5)
sungenerative (serve)	Biomarker positive (ie, MSI-H, NTRK, RET, TMB-H)	Targeted agents see BINV-Q (6)

	HR-Negative and HER2-Negative (Triple-Negative Breast Cancer; TNBC)				
Setting	Subtype/Biomarker	Regimen			
First Line	PD-L1 CPS ≥10 ^g regardless of germline <i>BRCA</i> mutation status ^b	Pembrolizumab + chemotherapy (albumin-bound paclitaxel, paclitaxel, or gemcitabine and carboplatin) ^h (Category 1, preferred)			
	PD-L1 CPS <10 ⁹ and no germline BRCA1/2 mutation ^b	Systemic chemotherapy see BINV-Q (5)			
	PD-L1 CPS <10 ^g and germline BRCA1/2 mutation ^b	 PARPi (olaparib, talazoparib) (Category 1, preferred) Platinum (cisplatin or carboplatin) (Category 1, preferred) 			
Second	Germline BRCA1/2 mutation ^b	PARPi (olaparib, talazoparib) (Category 1, preferred)			
Line	A	Sacituzumab govitecan ⁱ (Category 1, preferred)			
	Any	Systemic chemotherapy see BINV-Q (5)			
	No germline <i>BRCA1/2</i> mutation ^b and HER2 IHC 1+ or 2+/ISH negative ^d	Fam-trastuzumab deruxtecan-nxkie (Category 1, preferred)			
Third Line and beyond Biomarker positive (ie, MSI-H, NTRK, RET, TMB-H)		Targeted agents see BINV-Q (6)			
	Any	Systemic chemotherapy see BINV-Q (5)			

Antibody-Drug Conjugates – Part 1

Triple-Negative Breast Cancer

- Bar Y et al. **Dynamic HER2-low status** among patients with triple negative breast cancer (TNBC): The impact of **repeat biopsies.** ASCO 2023;Abstract 1005.
- Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. ESMO 2023; Abstract 3760.
- Loibl S et al. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. *Eur J Cancer* 2023;178:23-33.




Third Annual National General Medical Oncology Summit

Friday, March 22, 2024 — 7:00 PM – 9:00 PM

Keynote Session Special Feature: Clinicians with Cancer


How do you think a medical oncologist with metastatic breast cancer would feel about enrolling on a clinical trial of a novel agent or strategy, such as an antibodydrug conjugate, after exhausting all available treatment options?

DB-04: Updated OS and safety



The median follow-up was 18.4 months at initial reporting

primary analysis (data cutoff, January 11, 2022)



In the HR+ cohort and all patients, median OS was consistent with results from the primary analysis, showing a 31% reduction in risk of death for patients receiving T-DXd compared with those receiving TPC

Impact of repeat biopsies on HER2-low status among patients with TNBC

789 pts in the institutional TN database (2000-2022)

Overall study population: 512 pts with TNBC at diagnosis and at least one Bx with known HER2 status

Characteristics, no. (%)	TNBC cohort N=512
Age, median (range)	52 (25-97)
Age groups	
<i>≤</i> 50	238 (46%)
> 50	274 (54%)
Self reported race	
White	423 (83%)
Black/African American	34 (7%)
Asian	25 (5%)
Hispanic	14 (3%)
Other	8 (2%)
Not reported	8 (2%)
Stage at Dx	
1	145 (28%)
2	247 (48%)
3	74 (14%)
4	43 (8%)
Unknown	3 (1%)

Characteristics, no. (%)	TNBC cohort N=512
ER status	
Negative (<1%)	447 (87%)
Low (1-10%)	65 (13%)
NA therapy, no.	
Yes	278 (54%)
No	238 (45%)
Unknown	4 (1%)
Total no. of Bxs per pt	
1	194 (38%)
2	233 (45%)
3	48 (9%)
4	29 (6%)
≥5	8 (2%)

Retrospective study

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus TPC in metastatic TNBC

- HRQoL was assessed on day 1 of each treatment cycle using the EORTC QLQ-C30. Score changes from baseline were
 analysed using linear mixed-effect models for repeated measures. Stratified Cox regressions evaluated time to first
 clinically meaningful change of HRQoL.
 - Data collected up to C6D1
 - The analysis population comprised 236 patients randomized to SG and 183 to TPC.
- SG > TPS: global health status (GHS)/QoL, physical functioning, fatigue, and pain
- TPC> SG : nausea/vomiting and diarrhea
- SG arm had a significantly better QLQ-C30 summary score Least-Square (LS) mean change from baseline than TPC arm.
- Median TTW of GHS/QoL was similar in both treatment arms (14.1 weeks for SG and 15.1 weeks for TPC; HR Z 0.87, 95% CI 0.70 to 1.07; P Z 0.18)
- Median time to first clinically meaningful worsening was longer for SG than for TPC for physical functioning (22.1 versus 12.1 weeks, P < 0.001), role functioning (11.4 versus 7.1 weeks, P < 0.001), fatigue (7.7 versus 6.0 weeks, P < 0.05), and pain (21.6 versus 9.9 weeks, P < 0.001).
- SG prolongs progression-free survival and overall survival in patients with refractory/relapsed metastatic TNBC.
 - SG generally associated with greater improvements and delayed worsening of HRQoL scores compared with TPC supporting its use for patients with mTNBC over TPC


Antibody-Drug Conjugates – Part 2

Triple-Negative Breast Cancer

- Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase lb/II study. ESMO 2023;Abstract 379MO.
- Krop IE et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol 2023;41(36):5550-60.
- Zhang J et al. First-in-human/phase I trial of **HS-20089**, a **B7-H4 ADC**, in patients with advanced solid tumors. ESMO 2023;Abstract 381O.



Datopotamab deruxtecan (Dato-DXd) + durvalumab as first-line treatment for unresectable locally advanced/metastatic TNBC: Updated Arm 7 results from phase Ib/II BEGONIA study






PD-L1 expression

BEGONIA Arm 7: Dato-DXd + Durvalumab

Antitumour Responses in 1L a/mTNBC




Dotted lines indicate thresholds for partial response (-30%) and progressive disease (20%). PD-L1 expression variance exits with membranous staining (TAP), or 2) immunohistochemistry using the 22C3 antibody with expression defined as the parameter of PD-L1-staining tumour cells, lymphocytes, and macrophages, divided by the total number of viable tumour cells, multiplied by 100 (CPS). The best percentage change from baseline of target lessons cannot be calculated due to progression, withdrawal, or death, the value is imputed at +20%. Y Patients with PD as best overall response.

1L, first line, alm TNBC, advanced/metastatic triple-negative breast cancer, CI, confidence interval; CPS, combined positive score; CR, complete response; Dato-DXd, datopotamab deruxtecan; ORR, objective response rate; PD-L1, programmed cell dealh ligand-1; PR, partial response; TAP, turnour area positivity.

Schmid P et al ESMO 2023, Abstract # 379MO

BEGONIA: Durvalumab plus Dato-DXd

Progression-Free Survival and Duration of Response



- The most common AEs were gastrointestinal
- Stomatitis was the most common AE leading to Dato-DXd dose reduction (11) patients)
- There were 3 (5%) adjudicated treatment-related ILD/pneumonitis events (2) grade=2, 1 grade=1)
- The most frequent AESIs were for stomatitis (65%), rash (32%), dry eye (21%), hypothyroidism (14.5%), and keratitis (14.5%)

Courtesy of Priyanka Sharma, MD

Patients, n (%)	Dato-DXd + D N=62
Any AEs	62 (100)
Grade 3/4	35 (57)
Any treatment-related AEs ^a	62 (100)
Grade 3/4	27 (44)
Any serious AEs	14 (23)
Treatment-related	6 (10)
AEs leading to discontinuation of any treatments	10 (16)
AEs leading to death ^b	1 (2)
Dose adjustments	
Dato-DXd dose reduction	18 (29)
Dato-DXd dose delay	28 (45)
Durvalumab dose delay	31 (50)

Most frequently reported adverse events (≥15%) (N=62)

AE preferred term	Any grade, n (%)	Grade 3/4, n (%)
Nausea	40 (65)	0
Stomatitis	40 (65)	7 (11)
Alopecia	31 (50)	0
Constipation	29 (47)	1 (2)
Fatigue	28 (45)	1 (2)
Rash	20 (32)	0
Vomiting	16 (26)	1 (2)
Amylase increased	13 (21)	11 (18)
COVID-19	13 (21)	0
Dry eye	13 (21)	0
Decreased appetite	12 (19)	1 (2)
Pruritus	10 (16)	0
Cough	10 (16)	0



ADC plus IO combination in TNBC


- Combination of Dato-DXd plus Durva yielded robust activity in first line setting
 - Only 50% had prior chemotherapy for early-stage disease
 - Single arm design prohibits assessment of combination vs Dato-DXd monotherapy efficacy
 - Data-DXd monotherapy ORR in much heavily pre-treated patient population (TROPION-PanTumor01, Median of 3 prior lines of therapy): 33%
- Ocular toxicity: pretreatment ophthalmology evaluation required
- Stomatitis: Prophylactic management with steroid mouth wash

On-going Phase III trials of ADC plus IO in TNBC

- TROPION-Breast02 (recruiting): 1st line trial comparing Dato-DXd to investigator's choice chemotherapy in patients with mTNBC who are not candidates for PD-1/PD-L1 Inhibitor therapy (NCT05374512)
- TROPION-Breast03 (recruiting): Dato-DXd with or without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III TNBC with residual disease Following Neoadjuvant Therapy (NCT05629585)
- TROPION-Breast04 (recruiting): Randomized Study of Neoadjuvant Dato-DXd Plus durvalumab followed by adjuvant durvalumab Versus neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (NCT06112379)
- ASCENT-04 (recruiting): Sacituzumab Govitecan and Pembrolizumab Versus TPC and Pembrolizumab in Previously Untreated, Locally Advanced Inoperable or Metastatic TNBC (PD-L1+) (NCT05382286)
- ASCENT-05 (recruiting): Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice TNBC with Residual Invasive Disease after neoadjuvant Therapy and Surgery (NCT05633654)

Courtesy of Priyanka Sharma, MD

Patritumab deruxtecan (HER3-DXd) in previously treated HER3expressing metastatic breast cancer: Phase I/II trial




 Safety is reported for patients who received HER3-DXd 4.8 mg/kg (n=48), 6.4 mg/kg (n=98), and all patients (N=182^d)

Patritumab Deruxtecan (HER3-DXd)



- A fully human anti-HER3 IgG1 mAb (patritumab), covalently linked to
- · A topoisomerase I inhibitor payload, an exatecan derivative, via
- · A tetrapeptide-based cleavable linker



	7 Key Attributes of HER3-DXd
	Payload mechanism of action: topoisomerase I inhibitor and
	High potency of payload 8.1-4
	High drug to antibody ratio $\approx 8^{a,1,2}$
١	Payload with short systemic half-life #b2.3
	Stable linker-payload #24
•	Tumor-selective cleavable linker a.1-5
oad	Bystander antitumor effect #2.6

Patritumab Deruxtecar

Krop IE et al JCO 2023;41(36):5550-60.

Patients, n (%) Median treatment duration: 5.9 mo (range 0.7-30.6 mo)	4.8 mg/kg n=48	6.4 mg/kg n=98	All Doses N=182
Any TEAE	47 (97.9)	98 (100)	181 (99.5)
Associated with discontinuation	5 (10.4)	8 (8.2)	18 (9.9)
Associated with dose reduction	6 (12.5)	22 (22.4)	35 (19.2)
Associated with drug interruption	23 (47.9)	57 (58.2)	100 (54.9)
Associated with death	1 (2.1) ^b	6 (6.1) ^b	7 (3.8) ^b
Grade ≥3 TEAE	31 (64.6)	80 (81.6)	130 (71.4)
Treatment-related TEAE	47 (97.9)	97 (99.0)	180 (98.9)
Associated with death	0	1 (1.0)°	1 (0.5)°
Grade ≥3	27 (56.3)	76 (77.6)	120 (65.9)
Serious TEAE	7 (14.6)	23 (23.5)	38 (20.9)
Adjudicated treatment-related ILD ^d			
Grade 1	0	2 (2.0)	3 (1.6)
Grade 2	1 (2.1)	2 (2.0)	5 (2.7)
Grade 3	0	2 (2.0)	3 (1.6)
Grade 4	0	0	0
Grade 5	0	1 (1.0)	1 (0.5)
Total	1 (2.1)	7 (7.1)	12 (6.6)

HER3 was determined by IHC in archival tumor tissue (pretreatment samples [<6 months prior to HER3-DXd treatment]) -HER3-positive was defined as IHC 2+ and IHC 3+ for DE/DF cohorts and as ≥25% membrane positivity at 10x for DEXP cohorts. -HER3-high was defined as ≥75% membrane positivity at 10x -HER3-low was defined as ≥25% and <75% membrane positivity at 10x

- GI and hematologic toxicity were the most common TEAEs
- The rate of adjudicated treatment-related ILD was 7%; most cases were grade 1 and 2

Courtesy of Priyanka Sharma, MD

Clinical Activity of HER3-DXd Across BC Subtypes

Patritumab Deruxtecan U31402-A-J101

Outcomes (BICR per RECIST 1.1)	HR+/HER2-	TNBC	HER2+			
	(n=113)	(n=53)	(n=14)			
	HER3-High and -Low	HER3-High	HER3-High			
Confirmed ORR, % (95% Cla)	30.1	22.6	42.9			
	(21.8-39.4)	(12.3-36.2)	(17.7-71.1)			
Best overall response, % ^b						
PR	30.1	22.6	42.9			
SD	50.4	56.6	50.0			
PD	11.5	17.0	7.1			
NE	8.0	3.8	0.0			
DOR, median (95% CI), mo	7.2	5.9	8.3			
	(5.3-NE)	(3.0-8.4)	(2.8-26.4)			
PFS, median (95% CI), mo	7.4	5.5	11.0			
	(4.7-8.4)	(3.9-6.8)	(4.4-16.4)			
6-month PFS rate, % (95% CI)	53.5	38.2	51.6			
	(43.4-62.6)	(24.2-52.0)	(22.1-74.8)			
OS, median (95% CI), mo	14.6	14.6	19.5			
	(11.3-19.5)	(11.2-17.2)	(12.2-NE)			
HER3-DXd demonstrated antitumor activity across BC subtypes Antitumor activity was also demonstrated across the range of HER3 expression						

As a similar safety profile was seen with 4.8 mg/kg and 6.4 mg/kg

5.6 mg/kg dose is being evaluated in BC in many ongoing trials




#ASC022


Courtesy of Priyanka Sharma, MD lan E. Krop, MD, PhD Krop IE et al Clin Oncol 2023;41(36):5550-60.



First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors.



- B7 homolog 4 protein (B7-H4), a transmembrane glycoprotein in the B7 superfamily, is highly expressed in various types of solid tumors with low expression in normal tissues
- ➢ HS-20089 is a novel B7-H4 targeted ADC
 - Target; B7-H4, Toxin: topoisomerase I inhibitor (DAR:6)
 - protease-cleavable linker




- N=52 patients treated at 6 dose levels
- Mean of 3.7 prior therapy lines:
- N=48 with breast cancer (n=32 TNBC)
- ➢ MTD: 5.8 mg/kg.
- Most common Gr 3 TRAEs were hematological toxicity. Grade 1-2 N/V and LFT increase noted in >20% of patients
- There was no adverse event leading to death. No interstitial pneumonia or infusion reactions reported.

Zhang J et al. ESMO 2023; Abstract 3810.

Courtesy of Priyanka Sharma, MD

B7-H4 ADC, in patients with advanced solid tumors: Efficacy in TNBC

Figure 5. Best Percent Change of Target Lesions in TNBC



- > At potential target therapeutic doses of 4.8 and 5.8 mg/kg, the ORRs were 33.3% and 27.3%, respectively.
- > ORR in patients treated with prior IO (n=7): 42%
- > ? ORR in patients treated with prior ADC
- PFS and median duration of response not reported
- Expansion is ongoing

ADCs in TNBC: present and future

- TROP-2 ADCs with Topo-1 payload: SG approved regardless of HER2 low/zero (>1 Line)
 - Dato-DXd, SKB264 (MK-2870)
- HER2 ADC: T-DXd (Topo-1 payload) Approved for HER2 low mTNBC (> 1L)
- HER3 ADC: HER3-DXd (Topo 1 payload): In trials
- B7-H4 ADC: HS-20089 (Topo 1 payload): In trials
- Bispecific antibodies: In trials



- ? ADC with non-Topo 1 payload
- Very little is known about mechanisms of resistance:
 - ? Target, ? Payload, ? Both ? others
- ? ADC after ADC efficacy:
 - Optimal sequence for mTNBC?: Should level of target expression guide decisions? current methods of target level expression (IHC based) are not optimal to guide selection of therapy
 - Need quantitative assays

Will be an important question to answer if ADCs move in curative setting (Residual disease and Neoadjuvant trials are ongoing)

Courtesy of Priyanka Sharma, MD

Meet The Professor Optimizing the Management of Myelofibrosis

Thursday, February 1, 2024 5:00 PM – 6:00 PM ET

Faculty Stephen T Oh, MD, PhD

> Moderator Neil Love, MD



Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.

